Skip to content

Is NICE Going To Play Nice When Reviewing The High Cost of Orphan Drugs ?

October 5, 2012

       RAPS‘ (Regulatory Affairs Professionals Society) publication Regulatory Focus on July 23, 2012, announces that NICE (National Institute For Health & Clinical Excellence) will be reviewing the high cost of orphan drugs :  

        – UK’s Health Technology Assessment (HTA) group, National Institutes for Health and Clinical Excellence (NICE), is going to start reviewing and evaluating what it calls the “very high cost of drugs for people who suffer with rare conditions” under UK’s new Health and Social Care Act of 2012

         – NICE will conduct assessments of orphan drugs’ value relative to its cost, societal impact, and benefit to patients

          – NICE is to start this assessment April 2013.

 References

NICE July 20, 2012 News

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: